Handok introduced Actelion’s pulmonary hypertension therapy, ‘Opsumit’
Handok(President Young-jin Kim) launched a new Actelion’s pulmonary hypertension therapy, ‘Opsumit Tab 10mg(generic name: macitentan, hereinafter referring to Opsumit),’ in Korea.
After launching ‘Tracleer’ developed by Actelion, a innovative new drug development company at Switzerland, Handok h...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
